DK1740206T3 - PHEP, en aminosyrepermease af Staphylococcus Aureus - Google Patents

PHEP, en aminosyrepermease af Staphylococcus Aureus

Info

Publication number
DK1740206T3
DK1740206T3 DK05732793.4T DK05732793T DK1740206T3 DK 1740206 T3 DK1740206 T3 DK 1740206T3 DK 05732793 T DK05732793 T DK 05732793T DK 1740206 T3 DK1740206 T3 DK 1740206T3
Authority
DK
Denmark
Prior art keywords
phep
amino acid
staphylococcus aureus
acid permease
antigenic polypeptides
Prior art date
Application number
DK05732793.4T
Other languages
English (en)
Inventor
Simon J Foster
Original Assignee
Absynth Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Absynth Biologics Ltd filed Critical Absynth Biologics Ltd
Application granted granted Critical
Publication of DK1740206T3 publication Critical patent/DK1740206T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DK05732793.4T 2004-04-29 2005-04-08 PHEP, en aminosyrepermease af Staphylococcus Aureus DK1740206T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409559.2A GB0409559D0 (en) 2004-04-29 2004-04-29 Polypeptide
PCT/GB2005/001384 WO2005105845A2 (en) 2004-04-29 2005-04-08 Phep, an amino acid permease of staphylococcus aureus

Publications (1)

Publication Number Publication Date
DK1740206T3 true DK1740206T3 (da) 2011-10-17

Family

ID=32408236

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05732793.4T DK1740206T3 (da) 2004-04-29 2005-04-08 PHEP, en aminosyrepermease af Staphylococcus Aureus

Country Status (11)

Country Link
US (2) US7740869B2 (da)
EP (1) EP1740206B1 (da)
JP (1) JP4906713B2 (da)
CN (1) CN1988917A (da)
AT (1) ATE515270T1 (da)
AU (1) AU2005238265B2 (da)
CA (1) CA2564596A1 (da)
DK (1) DK1740206T3 (da)
ES (1) ES2369087T3 (da)
GB (1) GB0409559D0 (da)
WO (1) WO2005105845A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0917685D0 (en) * 2009-10-09 2009-11-25 Absynth Biologics Ltd Antigenic polypeptide
GB201106162D0 (en) 2011-04-12 2011-05-25 Absynth Biologics Ltd Combination vaccine
GB201206366D0 (en) * 2012-04-11 2012-05-23 Absynth Biologics Ltd Bacterial vaccine
CA2879272A1 (en) 2012-07-16 2014-01-23 Robert G.K. DONALD Saccharides and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593114B1 (en) * 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus

Also Published As

Publication number Publication date
EP1740206B1 (en) 2011-07-06
EP1740206A2 (en) 2007-01-10
GB0409559D0 (en) 2004-06-02
US8168204B2 (en) 2012-05-01
AU2005238265A1 (en) 2005-11-10
US20080057065A1 (en) 2008-03-06
US20110171237A1 (en) 2011-07-14
WO2005105845A3 (en) 2006-03-16
ATE515270T1 (de) 2011-07-15
CA2564596A1 (en) 2005-11-10
US7740869B2 (en) 2010-06-22
JP2008501318A (ja) 2008-01-24
CN1988917A (zh) 2007-06-27
AU2005238265B2 (en) 2011-08-18
ES2369087T3 (es) 2011-11-25
WO2005105845A2 (en) 2005-11-10
JP4906713B2 (ja) 2012-03-28

Similar Documents

Publication Publication Date Title
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
ATE426412T1 (de) Adjuvante influenza-vakzine
SE0301653D0 (sv) Novel compounds
NO20091976L (no) Nye forbindelser
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
NO345046B1 (no) Oral doseringsform
ATE461710T1 (de) Nipah-virus-impfstoffe
EP4043031A3 (en) Zika viral antigen constructs
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EA200702254A1 (ru) Вакцинная композиция, содержащая в-субъединицу термолабильного токсина e.coli и антиген и адъювант
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
DK1618128T3 (da) Tuberkulosevaccine med forbedret effektivitet
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
EA200601743A1 (ru) Выделенный полипептид реналазы и его применение
PL380950A1 (pl) Pewne związki amionoalkiloglukozaminidofosforanowe i ich zastosowanie
DK1740206T3 (da) PHEP, en aminosyrepermease af Staphylococcus Aureus
ATE422367T1 (de) Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von chronischen infektionen und neoplastischen erkrankungen und behandlungsverfahren dafür
ATE455789T1 (de) Substituierte nonadepsipeptide
WO2006100430A3 (en) Polypeptides
WO2010005513A3 (en) Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof